Therapy News and Research

RSS

NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it is introducing a new eye care product, i-Lid Cleanser.

23 Apr 2014

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

New study by the Cancer Science Institute of Singapore and National University Hospital Singapore suggests that a variant of a cell surface protein is an ideal target for developing drugs to treat gastric cancer

23 Apr 2014

tPA therapy improves outcomes for patients suffering acute ischemic stroke

Administering a clot-dissolving drug to stroke victims quickly — ideally within the first 60 minutes after they arrive at a hospital emergency room — is crucial to saving their lives, preserving their brain function and reducing disability.

23 Apr 2014

Diaverum acquires its seventh kidney centre in Chile

Diaverum, one of the world's leading renal care service providers, has acquired its seventh kidney centre Chile. The Diaseal clinic, located in Puente Alto, a highly populated and fast growing district in the south of capital Santiago, features 18 stations which are used to treat 100 patients with haemodialysis (HD).

23 Apr 2014

Glaucoma drug may help reverse obesity-related vision loss in women

An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health.

23 Apr 2014

Saint Louis University partners with SSM to offer post-professional residency program in orthopedic physical therapy

Saint Louis University's program in physical therapy is partnering with SSM Physical Therapy to offer a post-professional residency program in orthopedic physical therapy.The year-long residency prepares physical therapists to specialize in evaluating, treating and managing patients who have orthopedic problems.

23 Apr 2014

Study: Added benefit of turoctocog alfa is not proven

Turoctocog alfa (trade name: NovoEight) has been approved since November 2013 for the prevention and treatment of bleeding in patients with haemophilia A.

23 Apr 2014

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

Surefire Medical, Inc. announced that a symposium focused on the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial will be held during the European Conference on Interventional Oncology (ECIO) meeting taking place in Berlin, Germany April 23-26. T

23 Apr 2014

VHVI implants miniaturized HeartWare HVAD Pump through minimally invasive approach

Sometimes smaller is better. This is especially true of left ventricular assist devices, the mechanically operated heart pumps that are implanted in heart failure patients to bridge them to transplantation.

23 Apr 2014

New studies may offer hope for people with migraine

Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

23 Apr 2014

New FDA-approved device reduces seizures in patients with medication-resistant epilepsy

A recently FDA-approved device has been shown to reduce seizures in patients with medication-resistant epilepsy by as much as 50 percent. When coupled with an innovative electrode placement planning system developed by physicians at Rush, the device facilitated the complete elimination of seizures in nearly half of the implanted Rush patients enrolled in the decade-long clinical trials.

23 Apr 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Treating patients with nonmetastatic clear-cell renal cell carcinoma with the tyrosine kinase inhibitor axitinib could not only prevent disease progression, but also shrink tumours before surgery, show the results of a phase II trial.

22 Apr 2014

Surgery promising for non-metastatic RCC with thrombus

Almost half of patients with non-metastatic renal cell carcinoma who have tumour thrombus above the hepatic veins will survive for 5 years after surgery, indicate study results published in The Journal of Urology.

22 Apr 2014

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.

22 Apr 2014

Multiple lines of targeted therapy extend life for mRCC patients

Overall survival of patients with metastatic renal cell carcinoma is extended the more lines of targeted therapy they receive, shows an evaluation of a large retrospective multicentre database.

22 Apr 2014

Nocturnal incontinence poses major burden after female bladder reconstruction

Health-related quality of life is lower in women who have undergone radical cystectomy and neobladder reconstruction for bladder cancer than in the general female population, shows research.

22 Apr 2014

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois.

22 Apr 2014

Study explains biological processes of malignant cancer cells

Cancer cells may be known for their uncontrollable growth and spread, but they also differ from normal tissue in another manner: how they produce energy.

22 Apr 2014

ResMed launches new nasal and full face masks

ResMed expands its ultra-light, comfortable, and award-winning AirFit™ line of masks today with new nasal and full face options.

From ResMed Corp 22 Apr 2014

Therapy News and Research

NovaBay introduces new eye care product to help patients with eyelids irritation

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

tPA therapy improves outcomes for patients suffering acute ischemic stroke

Diaverum acquires its seventh kidney centre in Chile

Glaucoma drug may help reverse obesity-related vision loss in women

Saint Louis University partners with SSM to offer post-professional residency program in orthopedic physical therapy

Study: Added benefit of turoctocog alfa is not proven

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

VHVI implants miniaturized HeartWare HVAD Pump through minimally invasive approach

New studies may offer hope for people with migraine

New FDA-approved device reduces seizures in patients with medication-resistant epilepsy

FDA approves Cyramza to treat patients with advanced stomach cancer

Neoadjuvant targeted treatment shows feasibility for limited clear-cell RCC

Surgery promising for non-metastatic RCC with thrombus

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Multiple lines of targeted therapy extend life for mRCC patients

Nocturnal incontinence poses major burden after female bladder reconstruction

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

Study explains biological processes of malignant cancer cells

ResMed launches new nasal and full face masks

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News